Novo Nordisk Stock Soars in 2023 on Surging Demand for Diabetes and Weight Loss Drugs

Novo Nordisk stock has jumped over 40% in 2023, beating Apple and Microsoft stock.

Growth is being driven by diabetes and weight loss drugs Ozempic and Wegovy.

Novo Nordisk raised full-year sales outlook by 5% due to Ozempic and Wegovy demand.

Semaglutide found very effective in kidney disease study, halted early.

While beating Big Tech stocks now, Novo Nordisk lagged over past decade. AI may provide better long-term tailwind.